ReviewObesity reviews : an official journal of the International Association for the Study of Obesity2022
Obesity-related glomerulopathy: Current approaches and future perspectives.
Review in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Effect of dietary interventions on kidney function in adults with obesity without chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2026Pooled it
- Effects and Clinical Value of Peritoneal Dialysis on Water and Water Balance, Adverse Reactions, Quality of Life, and Clinical Prognosis in Patients with Decompensated Chronic Nephropathy: A Systematic Review and Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Review
- Risk factor obesity: treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- A Clinical Genetics-Driven Dual Diagnosis of Prader-Willi Syndrome Due to Mosaic Maternal UPD(15) andGenes · 2026Article
- Exploratory urinary microbiome and metabolome profiles in patients with calcium oxalate kidney stones: a pilot cross-sectional study.BMC nephrology · 2026Article
- GDF15 Improves Renal Injury Induced by Ectopic Lipid Deposition via AMPK/SIRT1 Pathway-Mediated Autophagy.Metabolites · 2026Article
- Normal-range urinary albumin-to-creatinine ratio and mortality risk in adults with obesity: a cohort study.Diabetology & metabolic syndrome · 2026Article
- Inflammatory biomarkers are associated with renal injury and partially explain the obesity-renal injury relationship in U.S. adolescents: a cross-sectional NHANES study.BMC nephrology · 2026Article
- Association of Phoenixin-14 with Body Mass Index Categories and Proteinuria in Adults with Type 2 Diabetes.Medicina (Kaunas, Lithuania) · 2026Article
- Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic.Clinical and experimental nephrology · 2026Review
- Obesity and subclinical kidney injury: a biomarker based assessment in Asian Indian adults.BMC nutrition · 2026Article
- Obesity and Its Clinical Implications in End-Stage Kidney Disease.Medicina (Kaunas, Lithuania) · 2026Review
- Bariatric Surgery Reverses ORG and Exhibits a Distinct Transcriptomic Profile Compared to Weight Loss Through a Low-Fat Diet.International journal of molecular sciences · 2026Article
- The Spectrum and Temporal Trends of Glomerular Diseases in Saudi Arabia: A Systematic Review of Biopsy-Based Studies.International journal of nephrology · 2026Review
- Multidimensional mechanisms of natural products in modulating metabolic dysfunction-associated kidney disease: recent advances and future perspectives.Frontiers in pharmacology · 2026Review
- Development and Validation of an Integrated Metabolism-Obesity Index for Screening Renal Impairment in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.Journal of diabetes research · 2026Article
- Oncostatin M mediates the causal relationship between obesity and chronic kidney disease: evidence from Mendelian randomization and experimental validation.Diabetology & metabolic syndrome · 2025Article
- Safflower injection against obesity-induced mice podocyte injury by improving insulin resistance through increasing renal INSR and eNOS expression.Renal failure · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity-related glomerulopathy (ORG) is a silent comorbidity which is increasing in incidence as the obesity epidemic escalates. ORG is associated with serious health consequences including chronic kidney disease, end-stage renal disease (ESRD), and increased mortality. Although the pathogenic mechanisms involved in the development of ORG are not fully understood, glomerular hemodynamic changes, renin-angiotensin-aldosterone system (RAAS) overactivation, insulin-resistance, inflammation and ectopic lipid accumulation seem to play a major role. Despite albuminuria being commonly used for the non-invasive evaluation of ORG, promising biomarkers of early kidney injury that are emerging, as well as new approaches with proteomics and metabolomics, might permit an earlier diagnosis of this disease. In addition, the assessment of ectopic kidney fat by renal imaging could be a useful tool to detect and evaluate the progression of ORG. Weight loss interventions appear to be effective in ORG, although large-scale trials are needed. RAAS blockade has a renoprotective effect in patients with ORG, but even so, a significant proportion of patients with ORG will eventually progress to ESRD despite therapeutic efforts. It is noteworthy that certain antidiabetic agents such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be useful in the treatment of ORG through different pleiotropic effects. In this article, we review current approaches and future perspectives in the care and treatment of ORG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.